UroGen Pharma Q2 2026: $50.4M Revenue Beat, Strong Outlook for ZUSDURI & UGN‑103
UroGen Pharma Q2 2026: $50.4 M revenue for ZUSDURI, 73% QoQ growth, beat estimates, new patent, strong outlook & rising share price.
2 minutes to read
UROGEN PHARMA LTD
UroGen Pharma Faces Investor Scrutiny and Legal Challenges Amid Stock Volatility
UroGen Pharma Ltd faces investor scrutiny and legal challenges, including a class action lawsuit and potential claims of securities law violations, amidst significant stock price volatility.
2 minutes to read
UroGen Pharma Ltd. Under Securities Fraud Investigation Amid FDA Trial Concerns
UroGen Pharma Ltd. is under investigation for potential securities fraud and faces FDA concerns over its bladder cancer drug UGN-102, prompting investor alert notices and a critical FDA advisory committee meeting on May 21, 2025.
2 minutes to read
UroGen Pharma Ltd: Pioneering Hope in Urological Cancer Treatment
UroGen Pharma Ltd is a clinical-stage biopharmaceutical company pioneering innovative therapies for urological conditions, with a focus on uro-oncology, and is a beacon of hope for patients battling these challenging diseases.
3 minutes to read
UroGen Pharma’s Breakthroughs in Urological Cancer Treatment Signal New Hope for Patients
UroGen Pharma Ltd is a clinical-stage biopharmaceutical company making significant strides in urological cancer treatment, with promising results from its clinical trials and a commitment to improving patient outcomes.
3 minutes to read